How Do You Treat PV Patients That Fail Hydroxyurea (HU)? Published 2015-07-21 Download video MP4 360p Recommendations 18:19 Biomarker and Surrogate Targets for Successful Therapy in Polycythemia Vera (PV) 02:44 A 45-year old with polycythemia vera not responding to hydroxyurea 10:40 AML On The Go - Minimal Residual Disease Eradication with Epigenetic 01:16 Treating with hydroxyurea 01:19 Dr. Silver on Hydroxyurea and Interferon in MPNs 06:58 Hydroxyurea... The Basics 1:21:29 Sauna Benefits Deep Dive and Optimal Use with Dr. Rhonda Patrick & MedCram 18:46 Approach to the Exam for Parkinson's Disease 26:55 What is Lumbar Stenosis? Symptoms, Causes & Benefits of Ultrasonic Technology 24:04 PUT SALT in this sacred corner of your house and See What Happens Next ! | BUDDHIST TEACHINGS 06:51 AML On The Go - Selective Inhibition of FLT3 by Gilteritinib 41:06 What is Cervical Stenosis? | Jeffrey Cantor, MD 1:56:10 Sunlight: Optimize Health and Immunity (Light Therapy and Melatonin) 07:09 AML On The Go: Targeted Therapy of IDH1/IDH2 Mutated AML 14:46 Excess Deaths at Night - Obstructive Sleep Apnea Explained Clearly 05:45 AMl On The Go - Gemtuzumab Ozogamicin in AML 10:16 The Future of AFib Treatment 08:51 120CML03 05:12 120CML02 Similar videos 05:50 Machine-learning to predict hydroxyurea failure & thromboembolic events in polycythemia vera 05:14 Case 1: A PV Patient with Disease Progression on Hydroxyurea 04:59 How Do We Approach the Problematic PV Patient? 09:19 Debate: Should JAK Inhibitors use be Limited to Hydroxyurea-resistant/intolerant PV Patients? - No 22:40 Treatment goals in Essential Thrombocythemia and Polycythemia vera 17:54 Current therapy options and clinical outcomes analysis in patients with PV 08:40 Managing Challenges with Traditional Treatments: Polycythemia Vera 19:49 What is the Current Standard of Care in Treating Polycythemia Vera (PV)? 04:54 Case 1: A Patient with Disease Progression on Hydroxyurea 13:09 Long-acting interferon: What is the difference? 26:34 Managing Essential Thrombocythemia in 2021 - Dr. Tiziano Barbui 33:02 Dr. John Mascarenhas, MD - PV Moving Beyond Hydroxyurea 17:02 Indication for cytoreductive therapy in ET and PV: Do we have it right? 15:55 Debate: Should JAK Inhibitors use be Limited to Hydroxyurea-resistant/intolerant PV Patients? - Yes 20:09 Clinical Discussion Regarding Choice of Therapy for Polycythemia Vera (PV) 01:44 Follow up of the phase 3 RESPONSE trial of ruxolitinib in polycythemia vera More results